Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.01 by 900 percent. This is a 42.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.442 million which missed the analyst consensus estimate of $33.725 million by 95.72 percent. This is a 77.60 percent decrease over sales of $6.437 million the same period last year.